Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study Tecentriq approval offers an alternative to chemotherapy for all eligible patients This approval marks Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the EU Basel, 5 May... Read more